Norway is a global leader in salmon farming and AI-enabled aquaculture, but Chinese organisations now dominate patent activity in the sector. This article explores how AI is transforming fish farming, the growing competitive and IP challenges facing Norwegian innovators, and the strategic steps businesses can take to protect their advantage in a rapidly evolving market.
Many technologies have dual-use potential, having both civilian and defence or military applications. Technologies originally developed for civilian applications may be subsequently exploited for defence or military applications. Alternatively, technologies may be developed via a ‘dual use by design’ approach, integrating dual-use directly into their development.
To mark World Quantum Day, Trainee Patent Attorney Henry Coop examines the current state of the quantum sector, the significance of the emerging IP landscape, and how Dehns’ expertise supports and advises innovators operating in this rapidly evolving field.
Celebrating International Women’s Day 2026: An interview with Mooncup
To mark International Women’s Day on Sunday 8th March, we speak with Mooncup Ltd about sustainable innovation, women’s health, and the role IP plays in supporting their business.
US Supreme court to give the “skinny” on generic drugs
In this insight, Biotechnology partner Kit Wilkins reviews the US Supreme Court’s decision to Consider “Skinny Labels” in Generic Drug Patent Dispute. The decision could result in significant implications of generic medicines in the US.
Otsuka v Sun Pharma: Australia Reformulates its Position on Patent Term Extension
In this insight, Holly Rocliffe from Dehns Biotechnology group explores the recently handed down decision in Otsuka Pharmaceutical Co Ltd v Sun Pharma ANZ Pty Ltd [2025] FCAFC 161[1], in which the Full Court of the Federal Court of Australia (Full Court) has ruled that patent term extension (PTE) is only available for patents which claim an active pharmaceutical ingredient (API).
The first decision from the UPC on sufficiency — handed down in the Amgen v. Sanofi case — provides the first clear guidance on how the court will address whether a patent’s disclosure is sufficient.
In this insight, Dehns Partner Rob Jackson and Conor Wilman from our Technology, Software and Engineering group explore the UPC’s Court of Appeal recent issues of two important decisions about how it will assess inventive step in patent cases.